Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
Authors
Keywords
Early breast cancer, Adjuvant endocrine therapy, Recurrence risk, Recurrence-free survival, Systematic literature review, Meta-analysis
Journal
BREAST
Volume 57, Issue -, Pages 5-17
Publisher
Elsevier BV
Online
2021-02-21
DOI
10.1016/j.breast.2021.02.009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up
- (2019) Sherry X. Yang et al. BREAST CANCER RESEARCH AND TREATMENT
- One-step Nucleic Acid Amplification Can Identify Sentinel Node-negative Breast Cancer Patients With Excellent Prognosis
- (2019) KENZO SHIMAZU et al. ANTICANCER RESEARCH
- St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
- (2019) Marija Balic et al. Breast Care
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
- (2019) Manuel Ruíz-Borrego et al. BREAST CANCER RESEARCH AND TREATMENT
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Breast cancer statistics, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer
- (2018) Armando E. Giuliano et al. ANNALS OF SURGICAL ONCOLOGY
- PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer
- (2018) Anne-Vibeke Lænkholm et al. JOURNAL OF CLINICAL ONCOLOGY
- Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
- (2018) Marco Colleoni et al. LANCET ONCOLOGY
- Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer
- (2018) Juliet Richman et al. Nature Reviews Clinical Oncology
- Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
- (2017) Ian Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
- (2017) Marloes G M Derks et al. LANCET ONCOLOGY
- Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
- (2017) Vivianne C G Tjan-Heijnen et al. LANCET ONCOLOGY
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype
- (2016) Mansoor Alramadhan et al. BREAST
- PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
- (2016) Jessie McGowan et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
- (2016) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer
- (2016) Pattaraporn Wangchinda et al. World Journal of Surgical Oncology
- Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study
- (2016) Junichi Kurebayashi et al. Breast Cancer
- Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
- (2016) Guiyun Sohn et al. Cancer Research and Treatment
- Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
- (2015) Otto Metzger Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
- (2015) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor
- (2015) MASAHIRO OHARA et al. Oncology Letters
- A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer
- (2014) Shannon Cope et al. BMC Medicine
- Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial
- (2014) Ann S. Knoop et al. EUROPEAN JOURNAL OF CANCER
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis
- (2014) Yan Sun et al. MEDICAL ONCOLOGY
- Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers
- (2013) Jeroen P Jansen et al. BMC Medicine
- Comparing Bayesian and Frequentist Approaches for Multiple Outcome Mixed Treatment Comparisons
- (2013) Hwanhee Hong et al. MEDICAL DECISION MAKING
- Incorporating data from various trial designs into a mixed treatment comparison model
- (2013) Susanne Schmitz et al. STATISTICS IN MEDICINE
- Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
- (2012) Georgia Salanti Research Synthesis Methods
- Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy
- (2011) J.L. Wright et al. BREAST
- Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen
- (2011) Yong Wha Moon et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
- (2011) David C. Hoaglin et al. VALUE IN HEALTH
- Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
- (2011) Jeroen P. Jansen et al. VALUE IN HEALTH
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now